used in JZP385-202-MCC placebo in the IMPD. clinical trials

A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants with Parkinson’s Disease

This study is testing a new medicine, suvecaltamide, for people with Parkinson's disease who have shaking (tremor) that's affecting their daily life. It aims to see if the medicine can make their tremor better and is safe to use over 17 weeks.